Zydus Cadila
Pharma sector can deliver 100 new drugs by 2047: Zydus chairman
Indian pharma industry is capable of delivering 100 new drugs by 2047 for global markets backed by enhanced research and development efforts, Zydus Lifesciences Chairman Pankaj R Patel said on Friday. Speaking at an event here, he stressed the need for innovation, capability building, and a focus on societal benefit. "I believe India can deliver 100 new chemical entities or new drugs to the world by 2047 and off course, it will require effort," Patel said while speaking at the SOUL leadership conclave 2025. He termed it a myth that drug discovery requires a billion dollars while emphasising that it is possible with the right approach. Patel also asserted that the people working in an organisation are the most valuable resource and pitched for an environment where people love to work. He also emphasised the evolving nature of leadership, highlighting the importance of humility, vision, and a global perspective. Patel also shared experiences, including the Prime Minister's proactiv
 "Pharma sector can deliver 100 new drugs by 2047: Zydus chairman")
Zydus Lifesciences unit gets 10 observations from USFDA after inspection
Zydus Lifesciences on Wednesday said the US health regulator has issued ten observations after inspecting its injectable manufacturing plant near Vadodara in Gujarat. The US Food and Drug Administration (USFDA) inspected the facility at Jarod near Vadodara from April 15 to April 23, the drug maker said in a regulatory filing. The inspection closed with ten observations, it added. The company will closely work with the USFDA to address and respond to the observations in an expeditious manner, Zydus Lifesciences said. Shares of the company were trading 2.79 per cent down at Rs 932.80 apiece on the BSE.
 "Zydus Lifesciences unit gets 10 observations from USFDA after inspection")
Jhunjhunwala's firm Rare in talks with Barclays to prepay Rs 500 crore loan
The loan was used to fund the acquisition of Zydus Cadila's animal healthcare business in 2021
 "Jhunjhunwala's firm Rare in talks with Barclays to prepay Rs 500 crore loan")
Cadila Healthcare changes name to Zydus Lifesciences Limited
Unveils 'innovation and care' centric corporate brand identity
 "Cadila Healthcare changes name to Zydus Lifesciences Limited")
Zydus Q3 net down 5% to Rs 500 cr as sales dip in US and domestic markets
Revenue from operations nearly flat at Rs 3,655 crore in reporting quarter
 "Zydus Q3 net down 5% to Rs 500 cr as sales dip in US and domestic markets")
Zydus Cadila starts supply of Covid-19 vaccine ZyCoV-D to govt
ZyCoV-D is a three-dose vaccine administered intradermally
 "Zydus Cadila starts supply of Covid-19 vaccine ZyCoV-D to govt")
Zydus starts supplying coronavirus vaccine ZyCoV-D from Ahmedabad facility
ZyCoV-D is one of the first plasmid DNA vaccines administered intradermally using a painless needle-free system in three doses.
 "Zydus starts supplying coronavirus vaccine ZyCoV-D from Ahmedabad facility")
Zydus gets final USFDA nod to market generic version of Vigabatrin tablets
Cadila Healthcare said group firm Zydus has received final approval from the US health regulator to market its generic version of Vigabatrin tablets
 "Zydus gets final USFDA nod to market generic version of Vigabatrin tablets")
Covid-19 vaccine stock-taking: Does India have enough to expand the drive?
Zydus Cadila's yet to be launched DNA plasmid vaccine ZyCoV-D is expected to add to the vaccine supply
 "Covid-19 vaccine stock-taking: Does India have enough to expand the drive?")
Zydus gets orphan drug designation from USFDA for antimalarial compound
The orphan drug designation provides eligibility for certain development incentives
Zydus gets nod for phase 2 clinical study in Australian CAPS patients
Zydus Cadila on Monday said it has received approval to commence Phase II clinical study of its upcoming product with patients suffering with Cryopyrin-Associated Periodic Syndromein Australia.
Zydus Cadila gets USFDA approval to market generic schizophrenia drug
Cariprazine is an atypical antipsychotic medication used for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar disorder.
 "Zydus Cadila gets USFDA approval to market generic schizophrenia drug")
ZyCoV-D to be launched in seven states first, says health ministry
Training of vaccinators complete on needle free injector system
Zydus Cadila's Covid vaccine ZyCoV-D to be used in seven states initially
ZyCov-D, which is the first Covid vaccine to be cleared by India's drug regulator for those aged 12 years and above, will only be administered to adults in the seven states
Zydus Cadila likely to launch Covid-19 vaccine ZyCoV-D next month
Meanwhile, Zydus is working with a Korean partner to commercialise ZyCoV-D in South Korea in 2022
Zydus Cadila gets USFDA nod to market generic cancer drug in US
The drug will be manufactured at the group's injectables manufacturing facility
Zydus Cadila gets USFDA nod for cancer drug with 180-days exclusivity
The company has received approval from the US Food and Drug Administration (USFDA) for the Nelarabine injection 250 MG/50ML, a generic version of Arranon injection
Zydus Cadila's Covid vax to be administered only to adults for now: Sources
The ministry has already placed a purchase order with the Ahmedabad-based firm for one crore doses of the vaccine.
Cadila Healthcare gets Central govt order to supply 10 mn doses of ZyCoV-D
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
 "Cadila Healthcare gets Central govt order to supply 10 mn doses of ZyCoV-D")
Top headlines: India to buy 10 mn doses of ZyCoV-D; Britannia Q2 net falls
Business Standard brings you the top headlines from today
